Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published May 5, 2021 | Supplemental Material + Submitted
Journal Article Open

Structure Revision of the Lomaiviticins


The lomaiviticins are dimeric genotoxic metabolites that contain unusual diazocyclopentadiene functional groups and 2–4 deoxyglycoside residues. Because only 6 of 19 carbon atoms in the monomeric aglycon unit are proton-attached, their structure determination by NMR spectroscopic analysis is difficult. Prior structure elucidation efforts established that the two halves of the lomaiviticins are joined by a single carbon–carbon bond appended to an oxidized cyclohexenone ring. This ring was believed to comprise a 4,5-dihydroxycyclohex-2-ene-1-one. The bridging bond was positioned at C6. This structure proposal has not been tested because no lomaiviticin has been prepared by total chemical synthesis or successfully analyzed by X-ray crystallography. Here, we disclose microED studies which establish that (−)-lomaiviticin C contains a 4,6-dihydroxy-cyclohex-2-ene-1-one residue, that the bridging carbon–carbon bond is located at C5, and that the orientation of the cyclohexenone ring and configuration of the secondary glycoside are reversed, relative to their original assignment. High-field (800 MHz) NMR analysis supports the revised assignment and suggests earlier efforts were misled by a combination of a near-zero ³J_(H₄,H₅) coupling constant and a ⁴J_(C,H) coupling interpreted as a ³J_(C,H) coupling. DFT calculations of the expected ¹³C chemical shifts and C–H coupling constants provide further robust support for the structure revision. Because the interconversion of lomaiviticins A, B, and C has been demonstrated, these findings apply to each isolate. These studies clarify the structures of this family of metabolites and underscore the power of microED analysis in natural product structure determination.

Additional Information

© 2021 American Chemical Society. Received 12 February 2021. Published online 26 April 2021. Published in issue 5 May 2021. The authors thank Duilio Cascio (UCLA-DOE Institute) for assistance in data processing. Financial support from the National Institutes of Health (R35-GM131913 to S.B.H), the David and Lucile Packard Foundation (Fellowship to H.M.N.), Bristol Myers Squibb (Unrestricted Grant in Synthetic Organic Chemistry to H.M.N.), and Yale University is gratefully acknowledged. Author Contributions. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. The authors declare no competing financial interest. Accession Codes. CCDC 2062671 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

Attached Files

Submitted - structure-revision-of-the-lomaiviticins.pdf

Supplemental Material - ja1c01729_si_001.pdf

Supplemental Material - ja1c01729_si_002.pdb

Supplemental Material - ja1c01729_si_003.pdb

Supplemental Material - ja1c01729_si_004.pdb

Supplemental Material - ja1c01729_si_005.pdb

Supplemental Material - ja1c01729_si_006.pdb


Files (8.4 MB)
Name Size Download all
6.9 kB Download
3.5 MB Preview Download
10.5 kB Download
4.8 MB Preview Download
13.9 kB Download
6.9 kB Download
10.5 kB Download

Additional details

August 20, 2023
October 20, 2023